KRAS and non-small cell lung carcinoma: 已有研究表明分子标志物在指导肺癌个体化治疗中起着重要作用。本研究旨在探讨非小细胞肺癌(non-small cell lung cancer, NSCLC)抗微管类药物靶点TUBB3(tubulin, beta 3 class III)/STMN1(stathmin 1)基因表达水平与EGFR(epidermal growth factor receptor)、KRAS(Kirsten rat sarcoma viral oncogene homolog)、BRAF(v-raf murine sarcoma viral oncogene homolog B)、PI3K(phosphatidylinositol-4, 5-bisphosphate 3-kinase)基因突变的相关性,为NSCLC预后及药物疗效判断提供参考依据。